Our monthly Discussion Groups are hosted by a panel of leading industry experts who explore some of the key issues facing biologics research & development today.
Register below to receive a live stream of the discussion as well a complimentary report outlining the key findings and conclusions covered.
Taking place Friday 13 May 2022 | 15:00 BST (09:00 EST)
Taking place Thursday 16 June 2022 | 15:00 BST (09:00 EST)
Reports and write-ups pertaining to previous Discussion Groups are available in our In-Depth section.
Discussion Group Leaders:
Biotherapeutics representing an exciting class of modalities have been gaining renewed attention over the past few years, though challenges still remain. Their analytical development is one area with a lot of promise thanks to new platforms and softwares available. In addition to this, there are advancements pertaining to their characterisation and using of AI/ML. This live session brings together experts to look at the latest developments in the field for an hour of a discussion on automation, instrumentation, real-time release testing, and novel technologies.
Panel Discussion: Analytical Development for Diverse Modalities
Moderator: Amy Than, Senior Principal Scientist, Pfizer
With the recent advancements of antibody engineering technologies, techniques and methods, the market has seen an expansion. This growth is largely attributed to our better understanding of new modalities, smarter ways of choosing our targets and ensuring their quality, though challenges still remain. Our September discussion groups brings together an exclusive panel of key opinion leaders discussing the key factors behind the market’s growth, its priorities, future outlook & challenges.
Presentation: Antibody Discovery At Novo Nordisk
Speaker: Erik Vernet, Director, Antibody technology, Novo Nordisk
Panel Discussion: Oral Delivery of Biologics – Current Challenges & Opportunities
Moderator: Erik Vernet, Director, Antibody Technology, Novo Nordisk
Recent market demands for bispecific antibodies can largely be attributed to the application of existing commercially available products to other multiple indications. Currently, there are 2 bispecific antibodies commercially available on the market and over 200 in clinical trials. The future for the research and development of bispecific and multi-specific antibodies remains highly progressive and profitable, driven by the fact that an increasing number of big and small pharmaceutical companies are allocating their resources and are collaborating with other stakeholders of the industry. Challenges remain, however, and in our next biologics discussion group we bring together an exclusive panel of key opinion leaders to discuss the key factors behind the market’s growth, priorities, future outlook & challenges.
Panel Discussion: Bi-and Multi-Specific Antibodies – Formats, Applications, and Paths to the Clinic
Discussion Group Leaders: